Last reviewed · How we verify
NCT07242807: MIST
Minimally Invasive Prostate Interventions Registry (MIST Study)
trial testing No intervention in Benign Prostatic Hyperplasia (BPH) in 2,000 participants. Not yet recruiting.
30 December 2028
Quick facts
| Lead sponsor | Necmettin Erbakan University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 25 March 2026 |
| Primary completion | 30 December 2028 |
| Estimated completion | 30 December 2031 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- No intervention
Conditions studied
- Benign Prostatic Hyperplasia (BPH) — all drugs for Benign Prostatic Hyperplasia (BPH) →
- Minimal Invasive Surgery — all drugs for Minimal Invasive Surgery →
- LUTS — all drugs for LUTS →
Sponsor
Necmettin Erbakan University
Who can join
40 and older, male only, with Benign Prostatic Hyperplasia (BPH) or Minimal Invasive Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter prospective patient registry designed to evaluate clinical, functional, and safety outcomes after minimally invasive prostate interventions (MIST) performed for benign prostatic obstruction (BPO) secondary to benign prostatic hyperplasia (BPH). The interventions included in this registry represent standard-of-care treatment options and may include Rezum water vapor therapy, UroLift prostatic urethral lift, Aquablation, prostatic artery embolization (PAE), iTind, transperineal laser ablation (TPLA), transurethral needle ablation (TUNA), and transurethral microwave therapy (TUMT). The registry collects standardized data using a secure REDCap platform from participating international centers. Data elements include demographic characteristics, comorbidities, medication use, laboratory parameters, prostate volume assessments, uroflowmetry, post-void residual measurements, patient-reported symptom scores, sexual function assessments, intraoperative details, complications (classified using Clavien-Dindo), and postoperative recovery parameters. Follow-up visits occur at 1, 3, 6, 12, 24, and 36 months, with an optional extended follow-up at 72 months to assess long-term durability and reintervention-free survival. The primary aim of the study is to evaluate improvements in urinary symptoms (IPSS), quality of life, maximum urinary flow rate (Qmax), and post-void residual volume (PVR) following MIST procedures. Secondary objectives include assessing perioperative safety, catheterization duration, predictors of treatment success or failure, need for reintervention, and long-term preservation of continence and sexual function. This registry is observational and does not assign or modify any treatment. All procedures are performed based on local clinical practice and physician judgment. Prospective participants provide informed consent. Data collected will be used to generate real-world evidence to guide patient selection, optimize procedural outcomes, and compare clinical performance across different minimally invasive prostate interventions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07242807
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention
Trials testing the same drug.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
Other recruiting trials for Benign Prostatic Hyperplasia (BPH)
Currently open trials in the same condition.
- NCT07016620 — Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia · recruiting
- NCT06817733 — Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging · NA · recruiting
- NCT06062875 — Effects of TNF Blockade on Human BPH/LUTS · Phase 2 · recruiting
- NCT04266418 — The Evaluation of Banana Flower Stamens Extract on Prevention of Benign Prostatic Hyperplasia in Adults · NA · recruiting
- NCT04757116 — Post-Market Study to Assess iTind Safety in Comparison to UroLift · NA · recruiting
Other Necmettin Erbakan University trials
Trials by the same sponsor.
- NCT07128407 — PMT-Based Radiation Safety Training for Nurses: Randomized Controlled Trial. · NA · active not recruiting
- NCT07504770 — Surgical Glove Compression to Prevent Paclitaxel Neuropathy · NA · not yet recruiting
- NCT07442331 — The Effect of Game-Based Learning on Identifying Cognitive Distortions and Interpersonal Communication Competence in Nur · NA · completed
- NCT07396038 — INTRAOPERATIVE BLADDER INJURY ASSESSMENT IN TURBT USING BICEP · not yet recruiting
- NCT07274592 — The Effect of Psychoeducation Program Applied to Older Adults Based on Psychosocial Development Theory on Self-critical · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07242807 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Necmettin Erbakan University
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07242807.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing